A

Assembly Biosciences
D

ASMB

8.26000
USD
-0.28
(-3.28%)
مفتوح الان
حجم التداول
1
الربح لكل سهم
-5
العائد الربحي
-
P/E
-1
حجم السوق
61,977,960
أصول ذات صلة
ALNY
ALNY
4.900
(2.17%)
230.760 USD
A
ARWR
0.070
(0.63%)
11.180 USD
C
CRSP
1.490
(4.33%)
35.880 USD
E
EDIT
0.03500
(3.15%)
1.14500 USD
E
ESPR
0.00530
(0.55%)
0.96500 USD
I
IONS
0.210
(0.79%)
26.930 USD
N
NTLA
0.15000
(2.22%)
6.91000 USD
R
RGNX
-0.05000
(-0.93%)
5.34000 USD
V
VYGR
-0.02000
(-0.67%)
2.97000 USD
المزيد
الأخبار المقالات

العنوان: Assembly Biosciences

القطاع: Healthcare
الصناعة: Biotechnology
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.